FICHIT

Je m'inscris

VIROMETIX

0/5 (0 note(s))
Note donnée : aucune
Zurich
0
Develops breakthrough synthetic nanoparticle-based vaccines and immunotherapeutic drugs for respiratory diseases and cancer.
Virometix’ lead product is an epitope-optimized synthetic nanoparticle vaccine against Respiratory Syncytial Virus (RSV) – currently in preclinical development.
GHASPARIAN Arin
www.virometix.com
Private Equity

Fiche créée le 10/04/2016 par Guillaume   vue 9 fois.